{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:44:42Z","timestamp":1782564282600,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":317,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["RP68"],"award-info":[{"award-number":["RP68"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010065","name":"Morgan State University","doi-asserted-by":"publisher","award":["U54MD013376"],"award-info":[{"award-number":["U54MD013376"]}],"id":[{"id":"10.13039\/100010065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020627","name":"Central University of South Bihar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.crphar.2023.100166","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:55:36Z","timestamp":1700495736000},"page":"100166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mechanistic update of Trisenox in blood cancer"],"prefix":"10.1016","volume":"5","author":[{"family":"Ananta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Tchounwou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-3387","authenticated-orcid":false,"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nm.3441","article-title":"Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure","volume":"20","author":"Ablain","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.crphar.2023.100166_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","article-title":"Mechanisms of PTEN loss in cancer: it's all about diversity","volume":"59","author":"Alvarez-Garcia","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.crphar.2023.100166_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2017.05.039","article-title":"Targeting human telomerase RNA component using antisense oligonucleotide induces rapid cell death and increases ATO-induced apoptosis in APL cells","volume":"809","author":"Asghari-Kia","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.crphar.2023.100166_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2018.10.007","article-title":"Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: proposing novel therapeutic potential for BKM120","volume":"841","author":"Bashash","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.crphar.2023.100166_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2005-01-0241","article-title":"Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation","volume":"106","author":"Chou","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.crphar.2023.100166_bib6","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1038\/bcj.2015.25","article-title":"Acute promyelocytic leukemia: where did we start, where are we now, and the future","volume":"5","author":"Coombs","year":"2015","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib7","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2003-05-1412","article-title":"JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells","volume":"103","author":"Davison","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.crphar.2023.100166_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686445","article-title":"The combination of Gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells","volume":"11","author":"de Almeida","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.leu.2402807","article-title":"Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial","volume":"17","author":"de Botton","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.crphar.2023.100166_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ctrv.2007.05.001","article-title":"Arsenical-based cancer drugs","volume":"33","author":"Dilda","year":"2007","journal-title":"Cancer Treat Rev."},{"issue":"18","key":"10.1016\/j.crphar.2023.100166_bib11","doi-asserted-by":"crossref","first-page":"12034","DOI":"10.1074\/jbc.M708816200","article-title":"Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2","volume":"283","author":"Dolniak","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.crphar.2023.100166_bib12","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1084\/jem.20131121","article-title":"Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia","volume":"210","author":"Dos Santos","year":"2013","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.crphar.2023.100166_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.leukres.2008.09.035","article-title":"Apoptosis induction by (+) alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells","volume":"33","author":"Freitas","year":"2009","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.crphar.2023.100166_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/cbt.23760","article-title":"Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses","volume":"14","author":"Galvin","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.crphar.2023.100166_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1179\/1607845412Y.0000000008","article-title":"Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFk\u03b2-dependent induction of hTERT due to down-regulation of Pin1 transcription","volume":"17","author":"Ghaffari","year":"2012","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.crphar.2023.100166_bib16","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood.V91.11.4300","article-title":"Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells","volume":"91","author":"Giann\u00ec","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.crphar.2023.100166_bib17","doi-asserted-by":"crossref","first-page":"29989","DOI":"10.1074\/jbc.M109.090530","article-title":"Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide","volume":"285","author":"Goussetis","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.crphar.2023.100166_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jnci\/djh043","article-title":"Loss of the tumor suppressor PML in human cancers of multiple histologic origins","volume":"96","author":"Gurrieri","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.crphar.2023.100166_bib19","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/cancers12102807","article-title":"Retinoblastoma tumor suppressor protein roles in epigenetic regulation","volume":"12","author":"Guzman","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.crphar.2023.100166_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.20337","article-title":"Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60","volume":"94","author":"Han","year":"2005","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.crphar.2023.100166_bib21","first-page":"1081","article-title":"The post-translational modification, SUMOylation, and cancer","volume":"52","author":"Han","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.crphar.2023.100166_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1535-6108(04)00082-0","article-title":"Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis","volume":"5","author":"Hayakawa","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.crphar.2023.100166_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2867-13-25","article-title":"Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway","volume":"13","author":"Hu","year":"2013","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.crphar.2023.100166_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fonc.2020.00463","article-title":"Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK\/STAT3 signaling on targeting head and neck cancer initiating cells","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"issue":"32","key":"10.1016\/j.crphar.2023.100166_bib25","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.1039\/D1SC03119H","article-title":"Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin","volume":"12","author":"Hu","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.crphar.2023.100166_bib26","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1038\/s41598-019-45982-7","article-title":"Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells","volume":"9","author":"Huynh","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.crphar.2023.100166_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ijc.1220","article-title":"Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2+\u2010dependent production of superoxide","volume":"92","author":"Iwama","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.crphar.2023.100166_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","article-title":"PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3","volume":"18","author":"Jeanne","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.leukres.2007.06.021","article-title":"Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid","volume":"32","author":"Jiang","year":"2008","journal-title":"Leuk. Res."},{"issue":"7 Pt A","key":"10.1016\/j.crphar.2023.100166_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.bbamcr.2016.03.019","article-title":"PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells","volume":"1863","author":"Jo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.crphar.2023.100166_bib31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.leukres.2014.05.019","article-title":"Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide","volume":"38","author":"Jung","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.crphar.2023.100166_bib32","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/sj.leu.2403120","article-title":"Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1","volume":"17","author":"Kajiguchi","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.crphar.2023.100166_bib33","doi-asserted-by":"crossref","first-page":"36062","DOI":"10.1074\/jbc.M007204200","article-title":"Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase","volume":"275","author":"Kapahi","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib34","first-page":"193","article-title":"Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines","volume":"22","author":"Kian","year":"2020","journal-title":"Cell J."},{"key":"10.1016\/j.crphar.2023.100166_bib35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3892\/ol.2012.643","article-title":"Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines","volume":"3","author":"Kotowski","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.crphar.2023.100166_bib36","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.3390\/cancers13174402","article-title":"Therapeutic potential of targeting the SUMO pathway in cancer","volume":"13","author":"Kukkula","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.crphar.2023.100166_bib37","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-04-2800","article-title":"19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia","volume":"65","author":"Kumagai","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.crphar.2023.100166_bib38","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/tox.23299","article-title":"Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells","volume":"36","author":"Kumar","year":"2021","journal-title":"Environ. Toxicol."},{"issue":"1","key":"10.1016\/j.crphar.2023.100166_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-9966-33-42","article-title":"Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells","volume":"33","author":"Kumar","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"69","key":"10.1016\/j.crphar.2023.100166_bib40","doi-asserted-by":"crossref","first-page":"33138","DOI":"10.18632\/oncotarget.26025","article-title":"Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells","volume":"9","author":"Kumar","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.crphar.2023.100166_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22207","article-title":"PTrisenox induces cytotoxicity through phosphorylation of mitogen\u2010activated protein kinase molecules in acute leukemia cells","author":"Kumar","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.crphar.2023.100166_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib44","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.canlet.2009.04.035","article-title":"Arsenic trioxide induces apoptosis and G2\/M phase arrest by inducing Cbl to inhibit PI3K\/Akt signaling and thereby regulate p53 activation","volume":"284","author":"Li","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.crphar.2023.100166_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41419-017-0018-3","article-title":"Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.crphar.2023.100166_bib46","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.7150\/jca.29751","article-title":"Arsenic trioxide induces autophagic degradation of the FLT3\u2010ITDmutated protein in FLT3\u2010ITD acute myeloid leukemia cells","volume":"11","author":"Liu","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.crphar.2023.100166_bib48","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00277-015-2477-x","article-title":"Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients","volume":"94","author":"Lou","year":"2015","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2003-08-2743","article-title":"Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells","volume":"104","author":"Lunghi","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.leu.2403585","article-title":"Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells","volume":"19","author":"Lunghi","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000369242","article-title":"Insights into the all-trans-retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: a meta-analysis","volume":"134","author":"Ma","year":"2015","journal-title":"Acta Haematol."},{"issue":"7","key":"10.1016\/j.crphar.2023.100166_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158760","article-title":"All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis","volume":"11","author":"Ma","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044949","article-title":"Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms","volume":"7","author":"Maroui","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.crphar.2023.100166_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1196\/annals.1378.022","article-title":"Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells","volume":"1090","author":"Mathieu","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"14","key":"10.1016\/j.crphar.2023.100166_bib55","first-page":"3893","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.crphar.2023.100166_bib56","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12032-009-9294-9","volume":"27","author":"Momeny","year":"2010","journal-title":"Med. Oncol."},{"issue":"14","key":"10.1016\/j.crphar.2023.100166_bib57","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.3390\/ijms20143559","article-title":"Autophagy: new insights into mechanisms of action and resistance of treatment in acute promyelocytic leukemia","volume":"20","author":"Moosavi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13402-014-0167-7","article-title":"Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells","volume":"37","author":"Nakaoka","year":"2014","journal-title":"Cell. Oncol."},{"issue":"12","key":"10.1016\/j.crphar.2023.100166_bib59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm.1891","article-title":"Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation","volume":"14","author":"Nasr","year":"2008","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib60","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3109\/10428194.2010.501535","article-title":"Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells","volume":"51","author":"Nayak","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"20","key":"10.1016\/j.crphar.2023.100166_bib61","doi-asserted-by":"crossref","first-page":"32550","DOI":"10.18632\/oncotarget.15925","article-title":"High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro","volume":"8","author":"Noguera","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.crphar.2023.100166_bib62","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.leukres.2010.02.016","article-title":"Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line","volume":"34","author":"Noh","year":"2010","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib63","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1158\/0008-5472.CAN-11-3159","article-title":"The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA","volume":"72","author":"Rabellino","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.crphar.2023.100166_bib64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/bi801988x","article-title":"Arsenic (III) species inhibit oxidative protein folding in vitro","volume":"48","author":"Ramadan","year":"2009","journal-title":"Biochemistry"},{"issue":"18","key":"10.1016\/j.crphar.2023.100166_bib65","doi-asserted-by":"crossref","first-page":"10173","DOI":"10.1073\/pnas.180290497","article-title":"Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins","volume":"97","author":"Rego","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.crphar.2023.100166_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2162-3619-3-9","article-title":"Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells","volume":"3","author":"Rogers","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.crphar.2023.100166_bib67","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1021\/acs.jproteome.7b00001","article-title":"Human regulatory protein ki-1\/57 is a target of SUMOylation and affects PML nuclear body formation","volume":"16","author":"Saito","year":"2017","journal-title":"J. Proteome Res."},{"issue":"19","key":"10.1016\/j.crphar.2023.100166_bib68","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.crphar.2023.100166_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2010.32.1067","article-title":"Modern approaches to treating acute promyelocytic leukemia","volume":"29","author":"Sanz","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.crphar.2023.100166_bib70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.arcmed.2020.06.002","article-title":"c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K\/NF-\u03baB Axis","volume":"51","author":"Sayyadi","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.crphar.2023.100166_bib71","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1080\/15384101.2017.1338221","article-title":"Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein","volume":"16","author":"Sheldon","year":"2017","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.crphar.2023.100166_bib72","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high-quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"Shen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.crphar.2023.100166_bib73","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1128\/MCB.19.7.5170","article-title":"PIC-1\/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia","volume":"19","author":"Sternsdorf","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.crphar.2023.100166_bib74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/ncb1716","article-title":"RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation","volume":"10","author":"Tatham","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.crphar.2023.100166_bib75","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","article-title":"Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia","volume":"97","author":"Tomita","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.crphar.2023.100166_bib76","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/bjc.2014.380","article-title":"Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells","volume":"111","author":"Valenzuela","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.crphar.2023.100166_bib77","doi-asserted-by":"crossref","first-page":"44988","DOI":"10.1074\/jbc.M207176200","article-title":"Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide","volume":"277","author":"Verma","year":"2002","journal-title":"J. Biol. Chem"},{"issue":"25","key":"10.1016\/j.crphar.2023.100166_bib78","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1182\/blood-2014-03-561852","article-title":"Clearance of PML\/RARA-bound promoters suffice to initiate APL differentiation","volume":"124","author":"Vitaliano-Prunier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.crphar.2023.100166_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.crphar.2023.100166_bib80","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.crphar.2023.100166_bib81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2018.06.027","article-title":"Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo","volume":"433","author":"Wahiduzzaman","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.728","article-title":"An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid","volume":"22","author":"Wang","year":"2004","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib83","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1751-553X.2009.01178.x","article-title":"Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival","volume":"32","author":"Wang","year":"2010","journal-title":"Int. J. Lab Hematol."},{"issue":"22","key":"10.1016\/j.crphar.2023.100166_bib84","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1158\/1078-0432.CCR-06-1354","article-title":"Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation","volume":"12","author":"Wetzler","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.crphar.2023.100166_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049283","article-title":"SUMOylation of GTF2IRD1 regulates protein partner interactions and ubiquitin-mediated degradation","volume":"7","author":"Widagdo","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.crphar.2023.100166_bib86","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/s41418-019-0480-9","article-title":"Autophagy and disease: unanswered questions","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.crphar.2023.100166_bib87","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/cbin.11563","article-title":"Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias","volume":"45","author":"Yousefnia","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.crphar.2023.100166_bib88","article-title":"Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: proposing a perception in APL treatment","volume":"26","author":"Zamani-Moghaddam","year":"2021","journal-title":"Cancer Treat Res. Commun."},{"issue":"12","key":"10.1016\/j.crphar.2023.100166_bib89","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1349-7006.2009.01340.x","article-title":"Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer","volume":"100","author":"Zhang","year":"2009","journal-title":"Cancer Sci."},{"issue":"5975","key":"10.1016\/j.crphar.2023.100166_bib90","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.crphar.2023.100166_bib91","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5732\/cjc.012.10073","article-title":"Role of autophagy in acute myeloid leukemia therapy","volume":"32","author":"Zhang","year":"2013","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"10.1016\/j.crphar.2023.100166_bib92","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.toxlet.2014.11.028","article-title":"Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells","volume":"232","author":"Zhang","year":"2015","journal-title":"Toxicol. Lett."},{"issue":"21","key":"10.1016\/j.crphar.2023.100166_bib93","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1073\/pnas.0502825102","article-title":"Systems analysis of transcriptome and proteome in retinoic acid\/arsenic trioxide-induced cell differentiation\/apoptosis of promyelocytic leukemia","volume":"102","author":"Zheng","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.crphar.2023.100166_bib94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2013.08.022","article-title":"Combination of arsenic trioxide and chemotherapy in small cell lung cancer","volume":"82","author":"Zheng","year":"2013","journal-title":"Lung Cancer"},{"issue":"1482","key":"10.1016\/j.crphar.2023.100166_bib95","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1098\/rstb.2007.2026","article-title":"Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy","volume":"362","author":"Zhou","year":"2007","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257123000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257123000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:45:50Z","timestamp":1762922750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257123000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":95,"alternative-id":["S2590257123000147"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2023.100166","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic update of Trisenox in blood cancer","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2023.100166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100166"}}